Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

You’ve likely heard of well-known GLP-1 medications like Ozempic or Wegovy but some individuals are opting for specially made, compounded alternatives.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...